Skye Bioscience, Inc. (SKYE)
Automate Your Wheel Strategy on SKYE
With Tiblio's Option Bot, you can configure your own wheel strategy including SKYE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SKYE
- Rev/Share 0.0
- Book/Share 1.1013
- PB 0.9716
- Debt/Equity 0.0084
- CurrentRatio 6.0857
- ROIC -1.1397
- MktCap 34286905.0
- FreeCF/Share -0.8811
- PFCF -0.9812
- PE -1.0015
- Debt/Assets 0.007
- DivYield 0
- ROE -0.6865
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | SKYE | Cantor Fitzgerald | Overweight | Neutral | -- | $2 | Oct. 6, 2025 |
| Downgrade | SKYE | Craig Hallum | Buy | Hold | -- | $2 | Oct. 6, 2025 |
| Initiation | SKYE | Evercore ISI | -- | Outperform | -- | $10 | Aug. 15, 2025 |
| Initiation | SKYE | William Blair | -- | Outperform | -- | -- | Feb. 28, 2025 |
| Initiation | SKYE | Scotiabank | -- | Sector Outperform | -- | $20 | Sept. 30, 2024 |
| Initiation | SKYE | JMP Securities | -- | Mkt Outperform | -- | $15 | Sept. 10, 2024 |
News
SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
Published: December 16, 2025 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Skye between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 16, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Skye Biosciences, Inc. ("Skye" …
Read More
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: December 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Dec. 16, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before January 16, 2026.
Read More
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Skye Bioscience, Inc. (SKYE) Shareholders
Published: December 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities lawsuit.
Read More
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit
Published: December 15, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Dec. 15, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Period"), of the important January 16, 2026 lead plaintiff deadline. So what: If you purchased Skye securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm
Published: December 15, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - December 15, 2025) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Skye Bioscience, Inc. (NASDAQ: SKYE) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Skye Bioscience caused the company to misrepresent or fail to disclose that: (i) nimacimab was less effective than represented; (ii) accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, public statements were materially false and misleading at all relevant times.
Read More
ROSEN, A LONGSTANDING LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SKYE
Published: December 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”), of the important January 16, 2026 lead plaintiff deadline.
Read More
SKYE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Skye Bioscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: December 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
New class action for Skye Bioscience Inc. (SKYE) investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 01/16/2026
Read More
Portnoy Law Firm Announces Class Action on Behalf of Skye Bioscience, Inc. Investors
Published: December 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Dec. 15, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Skye Bioscience, Inc., (“Skye” or the "Company") (NASDAQ: SKYE) investors of a class action on behalf of investors that bought securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”). Skye investors have until January 16, 2026 to file a lead plaintiff motion.
Read More
Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing
Published: December 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”) on behalf of investors who purchased or otherwise acquired Skye securities during the period of November 4, 2024 through October 3, 2025 (the “Class Period”), inclusive.
Read More
The Gross Law Firm Reminds Skye Bioscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2026 - SKYE
Published: December 15, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Dec. 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE). Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
SKYE DEADLINE: Faruqi & Faruqi Reminds Skye Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2026 - SKYE
Published: December 12, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Skye between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Dec. 12, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Skye Biosciences, Inc. ("Skye" or the …
Read More
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: December 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before January 16, 2026.
Read More
Levi & Korsinsky Notifies Skye Bioscience, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SKYE
Published: December 12, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Dec. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Skye Bioscience, Inc. investors who were adversely affected by alleged securities fraud between November 4, 2024 and October 3, 2025.
Read More
SKYE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Skye Bioscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: December 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
New class action for Skye Bioscience Inc. (SKYE) investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 01/16/2026
Read More
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
Published: December 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Skye between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Skye Biosciences, Inc. (“Skye” or the …
Read More
Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing
Published: December 09, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Dec. 9, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye" or the "Company") on behalf of investors who purchased or otherwise acquired Skye securities during the period of November 4, 2024 through October 3, 2025 (the "Class Period"), inclusive. Investor Deadline: Investors who purchased Skye securities during the Class Period may, no later than January 16, 2026 , seek to be appointed as a lead plaintiff representative of the class.
Read More
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: December 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before January 16, 2026.
Read More
Investors who lost money on Skye Bioscience, Inc.(SKYE) should contact The Gross Law Firm about pending Class Action - SKYE
Published: December 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE).
Read More
Shareholders that lost money on Skye Bioscience, Inc. (SKYE) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
Published: December 08, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Dec. 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE). Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Skye Bioscience, Inc. Class Action: Levi & Korsinsky Reminds Skye Bioscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2026 - SKYE
Published: December 05, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Dec. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Skye Bioscience, Inc. investors who were adversely affected by alleged securities fraud between November 4, 2024 and October 3, 2025.
Read More
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
Published: December 05, 2025 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Skye to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Skye between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 5, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Skye Biosciences, Inc. ("Skye" …
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
Published: December 04, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Skye between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Dec. 4, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Skye Biosciences, Inc. ("Skye" or the …
Read More
Portnoy Law Firm Announces Class Action on Behalf of Skye Bioscience, Inc. Investors
Published: December 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Dec. 04, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Skye Bioscience, Inc., (“Skye” or the "Company") (NASDAQ: SKYE) investors off a class action on behalf of investors that bought securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”). Skye investors have until January 16, 2026 to file a lead plaintiff motion.
Read More
SKYE Class Action Reminder: Skye Bioscience, Inc. Stockholders Should Contact Robbins LLP for Information About the Securities Class Action Lawsuit
Published: December 02, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Dec. 2, 2025 /PRNewswire/ -- Company: Skye Bioscience, Inc. (NYSE: SKYE) is a clinical stage biopharmaceutical company that focuses on developing molecules that modulate G protein-coupled receptors ("GPCRs") to treat obesity, overweight, and metabolic diseases. The Company's lead product candidate is nimacimab.
Read More
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: December 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before January 16, 2026.
Read More
SKYE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Skye Bioscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: December 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) and certain of its officers.
Read More
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Skye Bioscience and Perrigo and Encourages Investors to Contact the Firm
Published: November 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Skye Bioscience, Inc. (NASDAQ:SKYE) and Perrigo Company plc (NYSE:PRGO).
Read More
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
Published: November 28, 2025 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Skye between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - November 28, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Skye Biosciences, Inc. ("Skye" …
Read More
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: November 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 28, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before January 16, 2026.
Read More
SKYE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Skye Bioscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) and certain of its officers.
Read More
About Skye Bioscience, Inc. (SKYE)
- IPO Date 2014-11-26
- Website https://skyebioscience.com
- Industry Biotechnology
- CEO Punit S. Dhillon
- Employees 16